new in mmwr: jynneos mpox vaccine, mpox among transgender adults, and more

["morbidity and mortality weekly report \(mmwr\) \(cdc\)" <no-reply@xxxxxxxxxxxxxxxxxxxx>]

this week in mmwr: vol. 71, december 30, 2022

december 30, 2022

weekly report

demographic and clinical characteristics of mpox in persons who had previously received 1 dose of jynneos vaccine and in unvaccinated persons — 29 u.s. jurisdictions, may 22–september 3, 2022 analysis of mpox infections among unvaccinated persons and those who had received 1 jynneos vaccine dose ≥14 days before illness onset found that the odds of fever, headache, malaise, myalgia, and chills were significantly lower among vaccinated patients than among unvaccinated patients.

• epidemiologic and clinical features of mpox in transgender and gender-diverse adults — united states, may–november 2022
• early estimates of bivalent mrna vaccine effectiveness in preventing covid-19–associated emergency department or urgent care encounters and hospitalizations among immunocompetent adults — vision network, nine states, september–november 2022
• early estimates of bivalent mrna vaccine effectiveness in preventing covid-19–associated hospitalization among immunocompetent adults aged ≥65 years — ivy network, 18 states, september 8–november 30, 2022
• notes from the field: clinical and epidemiologic characteristics of mpox cases from the initial phase of the outbreak — new york city, may 19–july 15, 2022

read more

quickstats

 

percentage of emergency department visits for pain at which opioids were given or prescribed, by patient age and year — national hospital ambulatory medical care survey, united states, 2010–2020

pdf of this issue (link).

continuing education

read more

centers for disease control and prevention

1600 clifton rd   atlanta, ga 30329   1-800-cdc-info (800-232-4636)   tty: 888-232-6348
questions or problems  | 

------=_NextPart_621_E3980A64.E3980A64--